<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guidance for prescribing erythropoiesis stimulating agents (ESAs) and concomitant iron therapy in preterm neonates</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guidance for prescribing erythropoiesis stimulating agents (ESAs) and concomitant iron therapy in preterm neonates</h1>
<div class="graphic"><div class="figure"><div class="ttl">Guidance for prescribing erythropoiesis stimulating agents (ESAs) and concomitant iron therapy in preterm neonates</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="3">Medications</td> </tr> <tr> <td class="subtitle2_left"> </td> <td class="subtitle2_left">Route</td> <td class="subtitle2_left">Dose and frequency</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">ESAs (any of the following are acceptable)</td> </tr> <tr> <td class="indent1">Darbepoetin alfa</td> <td>SUBQ/IV</td> <td> <ul> <li>10 mcg/kg/dose once weekly</li> </ul> </td> </tr> <tr> <td class="indent1">Epoetin alfa</td> <td>SUBQ</td> <td> <ul> <li>400 units/kg/dose 3 times per week</li> </ul> </td> </tr> <tr> <td class="indent1">Epoetin alfa</td> <td>SUBQ</td> <td> <ul> <li>1200 units/kg/dose once weekly</li> </ul> </td> </tr> <tr> <td class="indent1">Epoetin alfa</td> <td>IV (in TPN)</td> <td> <ul> <li>200 units/kg per 24 hours daily</li> </ul> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Iron</td> </tr> <tr> <td class="indent1" colspan="3">Enteral iron (used in neonates tolerating enteral feeds)</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Ferrous sulfate*</li> </ul> </td> <td>PO</td> <td> <ul> <li>Initial dose: 6 mg elemental iron/kg once daily</li> <li>Max dose: 12 mg elemental iron/kg/day (for doses ≥8 mg elemental iron/kg/day, divide into 2 daily doses)</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">IV iron (an option for neonates not yet tolerating enteral feeds)</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Iron sucrose</li> </ul> </td> <td>IV</td> <td> <ul> <li>1 mg/kg daily, or</li> <li>1.5 mg/kg twice weekly, or</li> <li>3 to 6 mg/kg once weekly</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Iron dextran<sup>¶</sup></li> </ul> </td> <td>IV</td> <td> <ul> <li>1 mg/kg daily, or</li> <li>1.5 mg/kg twice weekly, or</li> <li>3 to 6 mg/kg once weekly</li> </ul> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Other supplements</td> </tr> <tr> <td class="indent1">Multivitamin</td> <td>PO</td> <td> <ul> <li>&lt;2 kg: 0.5 mL once daily</li> <li>≥2 kg: 1 mL once daily</li> </ul> </td> </tr> <tr> <td class="indent1">Folate</td> <td>PO</td> <td> <ul> <li>50 micrograms once daily</li> </ul> </td> </tr> <tr> <td class="indent1">Vitamin E</td> <td>PO</td> <td> <ul> <li>15 international units once daily</li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="3">Monitoring</td> </tr> <tr> <td colspan="3"> <ul class="decimal_heading"> <li>Check reticulocyte count, HCT or Hgb, ANC, and ferritin before starting ESA therapy and every 1 to 2 weeks while on treatment</li> <li>Hold ESA if ANC falls below 1000/microL; restart once ANC is in normal range</li> <li>Discontinue ESA if the neonate develops serious toxicity (thrombosis, hypertension, seizure)</li> <li>Monitor adequacy of iron supplementation with ret-He (if available) or serum ferritin: <ul> <li>Check at 14 days of age, then repeat every 2 to 4 weeks while on treatment</li> <li>If ferritin &gt;400 ng/mL, discontinue iron</li> <li>If ret-He is &gt;35 pg or ferritin &gt;200, decrease iron by 2 mg/kg/day</li> <li>If ret-He is &lt;29 pg or ferritin &lt;15 ng/mL, increase oral iron by 2 to 4 mg/kg/day; if ret-He or ferritin remains low despite maximal dose of oral iron, consider single dose of IV iron</li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="3">Treatment discontinuation</td> </tr> <tr> <td colspan="3"> <ul class="decimal_heading"> <li>Criteria for discontinuing ESA and iron therapy include ANY of the following: <ul> <li>HCT ≥50%</li> <li>Neonate's CGA is ≥35 weeks</li> <li>Serious toxicity (neutropenia, thrombosis, hypertension, seizure)</li> </ul> <p class="extra_spacing_top">It is <strong>not</strong> necessary to hold ESA or iron therapy after blood transfusions except in the case of double-volume exchange transfusion for alloimmune hemolytic anemia (in which case ESA and iron are held for 2 weeks)</p> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes our suggested approach to prescribing ESAs and concomitant iron and folate therapy in preterm neonates. The practice of using ESAs is not standardized and varies from center to center. ESAs may be used in neonates whose parents/caregivers refuse blood transfusions for religious reasons. In addition, some neonatal centers routinely use ESAs for prophylaxis in at-risk preterm neonates. This includes all ELBW infants and select VLBW infants (ie, infants with alloimmune hemolytic anemia, infants requiring frequent blood draws, and/or infants undergoing surgery). There is considerable practice variation regarding use of ESAs in this setting and the optimal approach is uncertain. Refer to UpToDate's topic on anemia of prematurity for additional detail.</div><div class="graphic_footnotes"><p>ESA: erythropoiesis stimulating agent; SUBQ: subcutaneous; IV: intravenous; TPN: total parenteral nutrition; PO: per os (by mouth); HCT: hematocrit; Hgb: hemoglobin; ANC: absolute neutrophil count; CGA: corrected gestational age; ret-He: reticulocyte hemoglobin content; ELBW: extremely low birth weight (&lt;1000 g); VLBW: very low birth weight (&lt;1500 g).</p>
<p>* Ferrous sulfate dosing is expressed in terms of elemental iron. Ferrous sulfate oral liquid preparations contain 20% elemental iron. Multiple product concentrations exist; use caution when ordering and switching between products.</p>
¶ A test dose of IV iron dextran is recommended prior to starting maintenance dosing.</div><div id="graphicVersion">Graphic 140970 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
